IL6 and IL6R as Prognostic Biomarkers in Colorectal Cancer
Biomolecules · 19.12.2024 · 14 (12) · 1629
DOI: 10.3390/biom14121629 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 19.12.2024. Verfasst von Kathryn A F Pennel und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Cancer Sciences, Wolfson Wohl Cancer Research Institute, University of Glasgow, Estate, Glasgow G61 1BD, UK. Hauptthemen laut MEDLINE: Interleukin-6, Colorectal Neoplasms, Biomarkers, Tumor, Receptors, Interleukin-6. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chief Scientific Office, Cancer Research UK, Beatson Cancer Charity.
Abstract (Originalsprache)
Colorectal cancer is the third most diagnosed malignancy worldwide and survival outcomes remain poor. Research is focused on the identification of novel prognostic and predictive biomarkers to improve clinical practice. There is robust evidence in the literature that inflammatory cytokine interleukin-6 (IL6) is elevated systemically in CRC patients and that this phenomenon is a predictor of poor survival outcome. However, evidence is more limited for the role of IL6 and its cognate receptor, IL6R, within the tumour epithelium and microenvironment. This study aimed to investigate IL6 and IL6R expression in a large cohort of retrospectively collected patient tumour specimens and determine association with clinical outcomes and characteristics. High expression of IL6R in the tumour epithelium was associated with reduced cancer-specific survival in patients with right-sided colon cancer. In these patients, high IL6R expression was also associated with an increased systemic neutrophil-to-lymphocyte ratio. A high number of copies of IL6 mRNA within the tumour-associated stroma, but not epithelium, was associated with reduced cancer-specific survival. The results from this study have validated IL6R as a marker of poor prognosis in a subgroup of CRC patients and identified the spatially resolved prognostic nature of intra-tumoural IL6 expression. This study has also highlighted the need for investigation of IL6/IL6R-targeted therapies as novel treatment strategies for patients with colon cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Cancer Sciences, Wolfson Wohl Cancer Research Institute, University of Glasgow, Estate, Glasgow G61 1BD, UK.
- Cancer Research UK Scotland Institute, Garscube Estate, Glasgow G61 1BD, UK.
- Department of Pathology, Queen Elizabeth University Hospital, Glasgow G51 4TF, UK.
- Academic Unit of Surgery, Glasgow Royal Infirmary, Glasgow G4 0SF, UK.
ORCID-Profile: Kathryn A F Pennel, Ahmad Kurniawan, Jean Quinn, Colin Nixon, Joanne Edwards
Förderung
- Chief Scientific Office
- Cancer Research UK
- Beatson Cancer Charity
- CRUK
Zitieren
APA
Pennel, K. A. F., Kurniawan, A., Samir Foad Al-Badran, S., Schubert Santana, L., Quinn, J., Nixon, C., Hatthakarnkul, P., Maka, N., Roxburgh, C., McMillan, D., & Edwards, J. (2024). IL6 and IL6R as Prognostic Biomarkers in Colorectal Cancer. Biomolecules, 14(12), 1629. https://doi.org/10.3390/biom14121629
Vancouver
Pennel KAF, Kurniawan A, Samir Foad Al-Badran S, Schubert Santana L, Quinn J, Nixon C, et al. IL6 and IL6R as Prognostic Biomarkers in Colorectal Cancer. Biomolecules. 2024;14(12):1629. doi:10.3390/biom14121629
BibTeX
@article{Pennel2024,
author = {Pennel, Kathryn A F and Kurniawan, Ahmad and Samir Foad Al-Badran, Sara and Schubert Santana, Leonor and Quinn, Jean and Nixon, Colin and Hatthakarnkul, Phimmada and Maka, Noori and Roxburgh, Campbell and McMillan, Donald and Edwards, Joanne},
title = {IL6 and IL6R as Prognostic Biomarkers in Colorectal Cancer},
journal = {Biomolecules},
year = {2024},
volume = {14},
number = {12},
pages = {1629},
doi = {10.3390/biom14121629}
}
EUVIMED